NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $2,339,194.20 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CEO Michael Davidson sold 64,708 shares of the stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $36.15, for a total transaction of $2,339,194.20. Following the completion of the transaction, the chief executive officer owned 459,859 shares of the company’s stock, valued at $16,623,902.85. This trade represents a 12.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

NewAmsterdam Pharma Price Performance

Shares of NAMS traded down $0.73 during trading hours on Thursday, hitting $34.28. 900,936 shares of the company were exchanged, compared to its average volume of 634,742. The firm has a fifty day simple moving average of $34.05 and a 200-day simple moving average of $32.88. The company has a market capitalization of $3.89 billion, a PE ratio of -19.81 and a beta of 0.06. NewAmsterdam Pharma Company N.V. has a one year low of $14.06 and a one year high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. Sell-side analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Institutional Trading of NewAmsterdam Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in NAMS. Capital World Investors lifted its position in NewAmsterdam Pharma by 17.1% during the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after purchasing an additional 1,434,986 shares during the period. Jennison Associates LLC raised its stake in shares of NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after buying an additional 1,252,451 shares during the last quarter. Duquesne Family Office LLC lifted its holdings in NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after buying an additional 1,091,525 shares during the period. Castle Hook Partners LP bought a new position in NewAmsterdam Pharma in the fourth quarter valued at approximately $38,062,000. Finally, Adage Capital Partners GP L.L.C. raised its position in shares of NewAmsterdam Pharma by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after acquiring an additional 1,062,359 shares during the last quarter. 89.89% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on NAMS shares. Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. Stifel Nicolaus lifted their price objective on NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. The Goldman Sachs Group lifted their price target on NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a report on Tuesday, December 2nd. Finally, Royal Bank Of Canada increased their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and an average target price of $47.00.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.